Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01582763 · ClinicalTrials.gov registry record
International Guillain-Barré Syndrome Outcome Study
A clinical trial, sponsored by Erasmus Medical Center.
- Completed
- Registry status
- 2,000
- Enrollment target
NCT01582763: Completed study, sponsored by Erasmus Medical Center.
NCT01582763 is a clinical trial that has completed, run by Erasmus Medical Center. The registered enrollment target is 2,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01582763 has completed, sponsored by Erasmus Medical Center.
- COMPLETED
- Registry status
- 2,000 participants
- Enrollment target
Study Summary
International GBS Outcome Study (IGOS) is a study conducted by the members of the Inflammatory Neuropathy Consortium (INC) and Peripheral Nerve Society (PNS) on disease course and outcome in Guillain-Barré syndrome (GBS). The IGOS aims to identify clinical and biological determinants and predictors of disease course and outcome in individual patients with Guillain-Barré syndrome, as early as possible after onset of disease.
Primary Outcome
7 scores for disability, ranging from a healthy state to dead; 0 = healthy state to 6 = dead
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2012-05-01 |
| Est. Completion | 2024-12-02 |
What the finished NCT01582763 record still lists
NCT01582763 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT01582763 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01582763 about?
NCT01582763 is a clinical study titled "International Guillain-Barré Syndrome Outcome Study". International GBS Outcome Study (IGOS) is a study conducted by the members of the Inflammatory Neuropathy Consortium (INC) and Peripheral Nerve Society (PNS) on disease course and outcome in Guillain-Barré syndrome (GBS). The IGOS aims to identify clinical and biological determinants and predictors...
What is the current status of trial NCT01582763?
This trial is currently completed. The enrollment target is 2,000 participants. The study started on 2012-05-01. Estimated completion is 2024-12-02.
Who is sponsoring clinical trial NCT01582763?
This trial is sponsored by Erasmus Medical Center, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI